Story thread · 2 reports / 2 sources
Valneva outlines $145M-$160M 2026 revenue guidance while Pfizer targets Lyme decisions within 12 months
seekingalpha.com · 10h · first report
The coverage
- EMA validates Pfizer-Valneva Lyme disease vaccine application
investing.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.